Vedolizumab-4014: A Phase 4, Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis

Project: Research project

Status	Finished
Effective start/end date	6/19/18 → 6/19/21

Project Details